Green Cross "Falsified HIV Blood Data"
japan's Minister of Health and Welfare, naoto Kan, has said that Green Cross Corp continued to sell unheated blood products for up to 10 months after it had been ordered by the MHW to stop doing so and had assured the MHW that it had complied (Marketletters passim).
The Ministry has discovered that Green Cross had sold about about 900 units of unheated blood products in 1985 and 1986 even though it had been ordered to stop. The company has admitted that it made a false report to the Ministry about the date on which it withdrew the contaminated products, but executive director Masayuki Nishida says that the report was "inadequate only," and not faked.
- The Japan Times reports that in 1983 the head of the MHW's research group for AIDS, Takeshi Abe, persuaded the head of the National Hemophiliac Friendship Association to request that the Ministry provide "a guaranteed supply of unheated blood products," even though the risk of HIV infection was already known.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze